Investigational drug · Phase 3
Atigotatug+Nivolumab
Also called: BMS-986489
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Extensive-Stage Small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "Atigotatug+Nivolumab"
First trial start
2025
Feb 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Atigotatug+Nivolumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Extensive-Stage Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Atigotatug+Nivolumab" as an intervention, largest first.
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06646276 · 530 participants (planned) · Start Feb 25, 2025 · Primary completion Aug 17, 2027
Drug: BMS-986489 (Atigotatug+Nivolumab); Atezolizumab and 2 more · For: Extensive-Stage Small Cell Lung Cancer
Sites: Daphne, Alabama; Hot Springs, Arkansas; Fort Myers, Florida · 183 sites in all
- BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)Pivotal-lookingActive, not recruiting
SCRI Development Innovations, LLCAcademic, hospital or other
NCT06773910 · 250 participants (planned) · Start Mar 11, 2025 · Primary completion May 2032
Drug: BMS-986489; Durvalumab · For: Limited Stage Small Cell Lung Cancer
Sites: Daphne, Alabama; Santa Barbara, California; Fort Myers, Florida · 34 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06799286 · 10 participants · Start May 7, 2025 · Primary completion Sep 9, 2026
Drug: BMS-986489 · For: Small Cell Lung Carcinoma
Sites: Beijing, China; Jinan, China; Linyi, China · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer.
Paz-Ares LG, O'Byrne KJ, Johnson ML, et al. · Clin Lung Cancer 2026
Also in development for Extensive-Stage Small Cell Lung Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- BMS-986012Phase 21 trial
Bristol Myers Squibb · Extensive-stage Small Cell Lung Cancer
- ECI830Phase 21 trial
Novartis · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.